Increased epigenetic age and granulocyte counts in the blood of Parkinson's disease patients.
Level 4 - case-series / case-control
Case-control study evaluating blood DNA methylation markers in Parkinson's disease cases versus controls.
PubMed 26655927 · doi:10.18632/aging.100859
What was done
DNA methylation-based biomarkers of aging ("epigenetic clock") were measured in peripheral blood samples from two ethnically distinct case-control cohorts (508 Caucasian and 84 Hispanic participants). The authors evaluated intrinsic epigenetic age acceleration (IEAA, independent of cell counts), extrinsic epigenetic age acceleration (EEAA, reflecting cell-count changes), and imputed leukocyte subtype proportions between Parkinson's disease (PD) patients and controls.
What was found
Blood from PD patients exhibited significantly accelerated epigenetic aging under both IEAA (p = 0.019) and EEAA (p = 6.1 × 10⁻³). Imputed immune profiles showed marked shifts in PD cases compared to controls: higher granulocyte counts (p = 1.0 × 10⁻⁹ in Caucasians, p = 0.00066 in Hispanics), fewer T helper cells (p = 1.4 × 10⁻⁶ in Caucasians, p = 0.0024 in Hispanics), and fewer B cells (p = 1.6 × 10⁻⁵ in Caucasians, p = 4.5 × 10⁻⁵ in Hispanics). Numerical effect sizes and baseline demographics were not reported in the abstract.
Why it matters
This study links Parkinson's disease to systemic immune remodeling and accelerated biological aging in peripheral blood, identifying granulocyte elevation and lymphocyte depletion as key immunological features across two ethnic groups.
Limits
The observational case-control design cannot determine whether accelerated epigenetic aging is a driver or a downstream consequence of Parkinson's disease. Blood cell compositions were estimated via methylation imputation rather than measured directly with hematology analyzers or flow cytometry. The abstract does not report medication status (such as dopaminergic therapy), disease duration, or severity.
Cited by
- supports Blood samples from Parkinson's disease patients show a slight epigenetic age acceleration of 1 to 2 years.
- supports Parkinson's disease patients have highly elevated neutrophil counts in blood.